-
Mashup Score: 0
Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Gastrointestinal (GI) malignancies encompass a broad range of tumors with limited treatment options, particularly for advanced disease. With the development and implementation of next-generation sequencing (NGS) in routine practice, molecular-targeting therapies have been increasingly incorporated into the treatment paradigm for various cancers. Several drugs have achieved tissue-agnostic…
Source: Trends in CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative chemotherapy remains debatable for gastric/GEJ adenocarcinoma with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H). PATIENTS AND METHODS NEONIPIGA (ClinicalTrials.gov identifier:…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report - 2 year(s) ago
Immunotherapy in synchronous MSI-H rectal adenocarcinoma and upper tract urothelial carcinoma: a case report
Source: jgo.amegroups.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 1Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy - 2 year(s) ago
A 43-year-old woman presented with recurrent metastatic colon cancer with metastases to the peritoneum after having initially been diagnosed with stage IIB colon cancer and deferring adjuvant chemotherapy. Circulating tumor DNA (ctDNA)-based liquid biopsy testing revealed microsatellite instability-high (MSI-H) status, which was also confirmed on tissue testing. This patient then underwent four…
Source: www.cureus.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 12Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma - PubMed - 2 year(s) ago
KRAS-WT PDAC represents 10.7% of PDAC and is enriched with targetable alterations, including immuno-oncologic markers. Identification of KRAS-WT patients in clinical practice may expand therapeutic options in a clinically meaningful manner.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Just out! @CCR_AACR multi-inst collab @carisls POA #pancsm clinically relevant #KRAS WT subset w/mol targets #PDAC #braf #fgfr2 #alk #ret #ntrk1 #nrg1 #erbb2 #msi #tmb @DrHendifar @paphilip @OncoAlert @m_khushman @marshalj23 @doctormikehall https://t.co/Xrt5oZz1Ak @CSCancerCare https://t.co/p6HGA9hshI
-
-
Mashup Score: 1A Case of Microsatellite Instability–High Colon Cancer in a Young Woman With Familial Adenomatous Polyposis - 2 year(s) ago
Two major molecular pathways of colorectal carcinogenesis, chromosomal instability (CIN) and microsatellite instability (MSI), are considered to be mutually exclusive. Distinguishing CIN from MSI-high tumors has considerable therapeutic implications, because patients with MSI-high tumors can derive considerable benefit from immune checkpoint inhibitors, and tumors that evolved through the CIN…
Source: JNCCNCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors - 2 year(s) ago
PURPOSE Next-generation sequencing (NGS) testing is being incorporated into routine standard of care for patients with cancer. Immune checkpoint inhibitors (CPIs) are approved for use in both tumor-specific and tumor-agnostic indications. We sought to determine tumor type–specific or tumor-agnostic correlations between mutations detected by NGS and response to CPIs. MATERIALS AND METHODS A…
Source: JCO Precision OncologyCategories: Latest Headlines, Oncologists2Tweet-
#NGS-based analysis of 26,004 patients treated with #immunotherapy: 1. high #TMB and #MSI combined better outcome, means they identify different patients; 2. specific genomic alterations predictive of resistance despite hTMB and MSI-H indicated @OncoAlert https://t.co/Wr88kCkgs7 https://t.co/r4Ty6zUcnT
-
-
Mashup Score: 0Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC - 3 year(s) ago
Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dr. Halfdanarson on the KEYNOTE-177 Trial in MSI-H/dMMR mCRC - 4 year(s) ago
Thorvardur (Thor) Halfdanarson, MD, discusses the KEYNOTE-177 trial in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Highlighting work by our #KOL speakers -> 4th Annual @CedarsSinai #GI Tumor Conf (3/18/23): @HJLenz59 @uscnorris 1L nivo/ipi in #MSI-H mCRC CM-142 https://t.co/NjWOMPRA3C + TRIBE/FIRE3 genomic analysis https://t.co/MnJzkyFpEy @CSCancerCare Register at: https://t.co/7s8rEqg0r4 https://t.co/MqL54xMj5e